Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma.

被引：7
|
作者：
Locke, Frederick Lundry
Ghobadi, Armin
Jacobson, Caron A.
Jacobsen, Eric D.
Miklos, David Bernard
Lekakis, Lazaros J.
Braunschweig, Ira
Oluwole, Olalekan O.
Lin, Yi
Siddiqi, Tanya
Deol, Abhinav
Reagan, Patrick Michael
Farooq, Umar
Bot, Adrian
Jiang, Yizhou
Rossi, John M.
Xue, Allen
Go, William Y.
Neelapu, Sattva Swarup
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[2] Washington Univ, Sch Med, St Louis, MO 14263 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[5] Univ Miami Hlth Syst, Sylvester Comprehens Care Ctr, Miami, FL USA
[6] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA
[7] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[8] Mayo Clin, Rochester, MN USA
[9] City Hope Natl Med, Duarte, CA USA
[10] Wayne State Univ, Karmanos Canc Ctr, Detroit, MI USA
[11] Univ Rochester, Med Ctr, Rochester, NY 14642 USA
[12] Univ Iowa, Iowa City, IA USA
[13] Kite, Santa Monica, CA USA
[14] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.3003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3003
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B cell lymphoma.
    Locke, Frederick Lundry
    Ghobadi, Armin
    Lekakis, Lazaros J.
    Miklos, David Bernard
    Jacobson, Caron A.
    Jacobsen, Eric D.
    Braunschweig, Ira
    Oluwole, Olalekan O.
    Siddiqi, Tanya
    Lin, Yi
    Reagan, Patrick Michael
    Farooq, Umar
    Deol, Abhinav
    Bot, Adrian
    Rossi, John M.
    Jiang, Yizhou
    Xue, Allen
    Go, William Y.
    Neelapu, Sattva Swarup
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Retreatment of Patients With Refractory Large B Cell Lymphoma With Axicabtagene Ciloleucel (Axi-Cel) in ZUMA-1
    Locke, Frederick
    Bartlett, Nancy
    Jacobson, Caron
    Oluwole, Olalekan
    Munoz, Javier
    Lekakis, Lazaros
    Topp, Max
    Avivi, Irit
    Kim, Jenny
    Chu, Rong
    Zheng, Lianqing
    Rossi, John
    Bot, Adrian
    Neelapu, Sattva
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 : S21 - S22
  • [3] DURABILITY OF ANSWERS IN THE ZUMA-1, PIVOTAL STUDY PHASE 2 OF AXICABTAGEN CILOLEUCEL (AXI-CEL) IN PATIENTS WITH LARGE CELL LYMPHOMA B REFRACTORY
    Locke, F. L.
    Ghobadi, A.
    Jacobson, C. A.
    Jacobsen, E.
    Miklos, D. B.
    Lekakis, L. J.
    Braunschweig, I
    Oluwole, O. O.
    Lin, Y.
    Siddiqi, T.
    Deol, A.
    Reagan, P. M.
    Farooq, U.
    Bot, A.
    Jiang, Y.
    Rossi, J. M.
    Xue, A.
    Go, W. Y.
    Neelapu, Sattva S.
    HAEMATOLOGICA, 2018, 103 : 95 - 96
  • [4] Outcomes of patients (pts) ≥ 65 years of age in ZUMA-1, a pivotal phase 1/2 study of axicabtagene ciloleucel (axi-cel) in refractory large B-cell lymphoma (LBCL).
    Neelapu, Sattva Swarup
    Jacobson, Caron A.
    Oluwole, Olalekan O.
    Munoz, Javier
    Deol, Abhinav
    Miklos, David Bernard
    Bartlett, Nancy L.
    Braunschweig, Ira
    Jiang, Yizhou
    Kim, Jenny J.
    Zheng, Lianqing
    Rossi, John M.
    Locke, Frederick Lundry
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Retreatment (reTx) of Patients with Refractory Large B Cell Lymphoma with Axicabtagene Ciloleucel (Axi-Cel) in ZUMA-1
    Locke, Frederick L.
    Bartlett, Nancy L.
    Jacobson, Caron A.
    Oluwole, Olalekan O.
    Munoz, Javier
    Lekakis, Lazaros J.
    Topp, Max S.
    Avivi, Irit
    Kim, Jenny J.
    Chu, Rong
    Zheng, Lianqing
    Rossi, John M.
    Bot, Adrian
    Neelapu, Sattva S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S265 - S265
  • [6] Durability of Response in ZUMA-1, the Pivotal Phase 2 Study of Axicabtagene Ciloleucel in Patients With Refractory Large B-Cell Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (08) : 16 - 18
  • [7] Retreatment (ReTx) of patients (Pts) with refractory large B cell lymphoma (LBCL) sith Axicabtagene Ciloleucel (Axi-Cel) in ZUMA-1
    Locke, F. L.
    Bartlett, N. L.
    Jacobson, C. A.
    Oluwole, O. O.
    Munoz, J.
    Lekakis, L. J.
    Topp, M. S.
    Avivi, I
    Kim, J. J.
    Chu, R.
    Zheng, L.
    Rossi, J. M.
    Bot, A.
    Neelapu, S. S.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 57 - 57
  • [8] Outcomes of Patients Aged 65 Years in ZUMA-1, a Pivotal Phase 1/2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Refractory Large B Cell Lymphoma
    Neelapu, Sattva S.
    Jacobson, Caron A.
    Oluwole, Olalekan O.
    Munoz, Javier
    Deol, Abhinav
    Miklos, David B.
    Bartlett, Nancy L.
    Braunschweig, Ira
    Jiang, Yizhou
    Kim, Jenny J.
    Zheng, Lianging
    Rossi, John M.
    Locke, Frederick L.
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 : S19 - S20
  • [9] Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1.
    Locke, Frederick Lundry
    Bartlett, Nancy L.
    Jacobson, Caron A.
    Oluwole, Olalekan O.
    Munoz, Javier
    Lekakis, Lazaros J.
    Topp, Max S.
    Avivi, Irit
    Kim, Jenny J.
    Chu, Rong
    Zheng, Lianqing
    Rossi, John M.
    Bot, Adrian
    Neelapu, Sattva Swarup
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] Durability of Response in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel in the Pivotal Phase 2 Study, ZUMA-1
    Locke, Frederick L.
    Ghobadi, Armin
    Jacobson, Caron A.
    Jacobsen, Eric
    Miklos, David B.
    Lekakis, Lazaros J.
    Braunschweig, Ira
    Oluwole, Olalekan O.
    Lin, Yi
    Siddiqi, Tanya
    Deol, Abhinav
    Reagan, Patrick M.
    Farooq, Umar
    Bot, Adrian
    Jiang, Yizhou
    Rossi, John M.
    Xue, Allen
    Go, William Y.
    Neelapu, Sattva S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S277 - S278
12345